Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

312 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Integrating molecular imaging and transcriptomic profiling in advanced HER2-positive breast cancer receiving trastuzumab emtansine (T-DM1): an analysis of the ZEPHIR clinical trial.
Rediti M, Fimereli D, Mileva M, Wimana Z, Venet D, Flamen P, Guiot T, de Vries EGE, Schröder CP, Menke-van der Houven van Oordt CW, Maetens M, Majjaj S, Larsimont D, Rothé F, Sotiriou C, Gebhart G. Rediti M, et al. Among authors: larsimont d. Clin Cancer Res. 2024 Oct 29. doi: 10.1158/1078-0432.CCR-24-1007. Online ahead of print. Clin Cancer Res. 2024. PMID: 39470686
Characterization and clinical evaluation of CD10+ stroma cells in the breast cancer microenvironment.
Desmedt C, Majjaj S, Kheddoumi N, Singhal SK, Haibe-Kains B, El Ouriaghli F, Chaboteaux C, Michiels S, Lallemand F, Journe F, Duvillier H, Loi S, Quackenbush J, Dekoninck S, Blanpain C, Lagneaux L, Houhou N, Delorenzi M, Larsimont D, Piccart M, Sotiriou C. Desmedt C, et al. Among authors: larsimont d. Clin Cancer Res. 2012 Feb 15;18(4):1004-14. doi: 10.1158/1078-0432.CCR-11-0383. Epub 2012 Jan 10. Clin Cancer Res. 2012. PMID: 22235100 Free PMC article.
N-Acetylcysteine breaks resistance to trastuzumab caused by MUC4 overexpression in human HER2 positive BC-bearing nude mice monitored by 89Zr-Trastuzumab and 18F-FDG PET imaging.
Wimana Z, Gebhart G, Guiot T, Vanderlinden B, Larsimont D, Doumont G, Van Simaeys G, Goldman S, Flamen P, Ghanem G. Wimana Z, et al. Among authors: larsimont d. Oncotarget. 2017 Apr 10;8(34):56185-56198. doi: 10.18632/oncotarget.17015. eCollection 2017 Aug 22. Oncotarget. 2017. PMID: 28915583 Free PMC article.
Genomic hotspots but few recurrent fusion genes in breast cancer.
Fimereli D, Fumagalli D, Brown D, Gacquer D, Rothé F, Salgado R, Larsimont D, Sotiriou C, Detours V. Fimereli D, et al. Among authors: larsimont d. Genes Chromosomes Cancer. 2018 Jul;57(7):331-338. doi: 10.1002/gcc.22533. Epub 2018 Mar 22. Genes Chromosomes Cancer. 2018. PMID: 29436103
Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer.
Richard F, Majjaj S, Venet D, Rothé F, Pingitore J, Boeckx B, Marchio C, Clatot F, Bertucci F, Mariani O, Galant C, Eynden GVD, Salgado R, Biganzoli E, Lambrechts D, Vincent-Salomon A, Pruneri G, Larsimont D, Sotiriou C, Desmedt C. Richard F, et al. Among authors: larsimont d. Clin Cancer Res. 2020 Dec 1;26(23):6254-6265. doi: 10.1158/1078-0432.CCR-20-2268. Epub 2020 Sep 17. Clin Cancer Res. 2020. PMID: 32943456
Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology.
Fumagalli D, Blanchet-Cohen A, Brown D, Desmedt C, Gacquer D, Michiels S, Rothé F, Majjaj S, Salgado R, Larsimont D, Ignatiadis M, Maetens M, Piccart M, Detours V, Sotiriou C, Haibe-Kains B. Fumagalli D, et al. Among authors: larsimont d. BMC Genomics. 2014 Nov 21;15(1):1008. doi: 10.1186/1471-2164-15-1008. BMC Genomics. 2014. PMID: 25412710 Free PMC article.
312 results